18F-FAPI PET/CT and MRI in Gastric Cancer
ConditionGastric Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-80
SponsorFirst Affiliated Hospital of Zhejiang University
About this trial
The purpose of this study was to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET/CT combined with multiparameter MRI in gastric cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients suspected or diagnosed with gastric cancer
18F-FAPI PET/CT has been performed
Gastric MRI with both non-contrast and contrast-enhanced scans performed
Disqualifiers
Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years;
Severe uncontrollable diseases or active infections;
Ineligible participants who cannot provide informed consent for the study;
Patients with suboptimal image quality in 18F-FAPI PET/CT
Trial population
The purpose of this study was to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET/CT combined with multiparameter MRI in gastric cancer. Primary endpoint: Diagnostic efficacy of 18F-FAPI PET/CT combined with multiparametric MRI in gastric cancer patients (sensitivity, specificity, accuracy) secondary end points: * To compare the diagnostic performance differences between 18F-FAPI PET/CT and contrast-enhanced MRI in the clinical application of gastric cancer; ② Analysis of diagnostic differences in the subgroup (pathological, genetic, etc.) of patients using 18F-FAPI PET/CT combined with multiparameter MRI; ③ Evaluation of 18F-FAPI PET/CT combined with multiparameter MRI in predicting the prognosis of gastric cancer.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
patients with suspected or confirmed gastric cancer who have undergone 18F-FAPI PET/CT and MRI (non-contrast + contrast-enhanced scans)
Diagnostic testA comparative study of 18F-FAPI PET/CT and contrast-enhanced MRI in gastric cancer patients to evaluate the differences in tumor detection sensitivity, specificity, and accuracy among various imaging modalities. The study aims to clarify their advantages in clinical applications for gastric cancer. The research will focus on analyzing the differences in tumor size, location, metastasis, and pathological characteristics detected by each imaging technique, and explore the potential of 18F-FAPI PET/CT combined with multiparametric MRI in improving the diagnostic accuracy and early detection of gastric cancer.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Diagnostic efficacy
Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms
Time frame
through study completion, an average of 1.5 yearSecondary outcomes
1
Standard uptake value （SUV）of tumor
This measure evaluates the association between baseline 18F-FAPI PET parameters (e.g., SUVmax, SUVmean).
Time frame
through study completion, 3-4 years2
Prognostic Value of Baseline 18F-FAPI PET for Progression-Free Survival (PFS) in High-Risk Patients
PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model.（PFS in months）
Time frame
through study completion, 3-4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: